The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
Abstract
Curcumin has a potent antiproliferative activity and can also potentiate the antitumor effect of gemcitabine. This study was undertaken to evaluate the activity and feasibility of gemcitabine in combination with curcumin in patients with advanced pancreatic cancer. Seventeen patients were enrolled in the study and received 8,000 mg of curcumin by mouth daily, concurrently with gemcitabine 1,000 mg/m(2) IV weekly × 3 of 4 wk; 5 patients (29%) discontinued curcumin after a few days to 2 wk due to intractable abdominal fullness or pain, and the dose of curcumin was reduced to 4,000 mg/day because of abdominal complaints in 2 other patients. One of 11 evaluable patients (9%) had partial response, 4 (36%) had stable disease, and 6 (55%) had tumor progression. Time to tumor progression was 1-12 mo (median 2½), and overall survival was 1-24 mo (median 5). Low compliance for curcumin at a dose of 8,000 mg/day, when taken together with systemic gemcitabine, may prevent the use of high doses of oral curcumin needed to achieve systemic effect. Further studies should be conducted to evaluate the ability of other formulations of curcumin to enhance the effect of chemotherapy in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Anticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 3,017
Curcumin: From ancient medicine to current clinical trials
Hatcher, H., Planalp, R., Cho, J., Torti, F. M., & Torti, S. V. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7452-4 · Cited by 1,843
Dose escalation of a curcuminoid formulation
Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., Boggs, M. E., Crowell, J., Rock, C. L., & Brenner, D. E. (2006) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-6-10 · Cited by 1,394
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Ng, C. S., Badmaev, V., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0024 · Cited by 1,331
Self-citationPhase I Clinical Trial of Oral Curcumin
Sharma, R. A., Euden, S. A., Platton, S. L., Cooke, D. N., Shafayat, A., Hewitt, H. R., Marczylo, T. H., Morgan, B., Hemingway, D., Plummer, S. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0744 · Cited by 1,257
Curcumin and cancer: An “old-age” disease with an “age-old” solution
Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., & Aggarwal, B. B. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.025 · Cited by 1,132
Cancer: Principles and Practice of Oncology
CLAUDINO, W. M., & BIGANZOLI, L. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00680.x · Cited by 855
Li, L., Braiteh, F. S., & Kurzrock, R. (2005) · Cancer · doi:10.1002/cncr.21300 · Cited by 644
Urdaneta, A. B. (1972) · PubMed · Cited by 632
Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 595
Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., Bueso-Ramos, C. E., & Price, J. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1192 · Cited by 584
Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J., & Aggarwal, B. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4257 · Cited by 578
Garcea, G., Berry, D. P., Jones, D. J. L., Singh, R., Dennison, A. R., Farmer, P. B., Sharma, R. A., Steward, W. P., & Gescher, A. J. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.120.14.1 · Cited by 494
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Turmeric and Curcumin as Topical Agents in Cancer Therapy
Kuttan, R., Sudheeran, P. C., & Josph, C. D. (1987) · Tumori Journal · doi:10.1177/030089168707300105 · Cited by 293
Storniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., & Schilsky, R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990315)85:6<1261::aid-cncr7>3.0.co;2-t · Cited by 259
Patel, B. B., Sengupta, R., Qazi, S., Vachhani, H., Yu, Y., Rishi, A. K., & Majumdar, A. P. N. (2008) · International Journal of Cancer · doi:10.1002/ijc.23097 · Cited by 208
Strategy and planning for chemopreventive drug development: Clinical development plans II
Kelloff, G. J., Crowell, J. A., Hawk, E. T., Steele, V. E., Lubet, R. A., Boone, C. W., Covey, J. M., Doody, L. A., Omenn, G. S., Greenwald, P., et al. (1996) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240630705 · Cited by 196
ANTITUMOR, ANTI-INVASION, AND ANTIMETASTATIC EFFECTS OF CURCUMIN
Kuttan, G., Kumar, K. B. H., Guruvayoorappan, C., & Kuttan, R. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-46401-5_6 · Cited by 153
Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Bisht, S., & Maitra, A. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309789054933 · Cited by 124
Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines
Lev‐Ari, S., Vexler, A. M., Starr, A., Ashkenazy‐Voghera, M., Greif, J., Aderka, D., & Ben‐Yosef, R. (2007) · Cancer Investigation · doi:10.1080/07357900701359577 · Cited by 117
Mechanisms of curcumin induced gastric ulcer in rats.
Gupta, B., Kulshrestha, V., Rk, S., & Dn, P. (1980) · PubMed · Cited by 24
Van Dau, N., Ham, N. N., Khac, D. H., Lam, N. T., Son, P. T., Tan, N. T., Van, D. D., Dahlgren, S., Grabe, M., Johansson, R., et al. (1998) · Phytomedicine · doi:10.1016/s0944-7113(98)80056-1 · Cited by 15
(2001) · PubMed
(2001) · PubMed
Cited by
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9432-8 · Cited by 2,110
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01614 · Cited by 1,086
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13621 · Cited by 1,053
A Review of Curcumin and Its Derivatives as Anticancer Agents
Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051033 · Cited by 949
Discovery of curcumin, a component of golden spice, and its miraculous biological activities
Gupta, S. C., Patchva, S., Koh, W., & Aggarwal, B. B. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05648.x · Cited by 856
Metadata
- Authors
- Epelbaum, R., Schaffer, M., Vizel, B., Badmaev, V., & Bar-Sela, G.
- Venue
- Nutrition and Cancer
- Publisher
- Informa UK Limited
- Published
- 2010-11-05
- Volume
- 62
- Issue
- 8
- Pages
- 1137-1141
- ISSN
- 0163-5581 (ISSN-L)
- 1532-7914
- OpenAlex
- W2010573152
- Cited by
- 282
- References
- 28
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.